EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non–Small Cell Lung Cancer-Reference-Cited by-全球学者库

EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non–Small Cell Lung Cancer

Published:2021-11 Issue:6 Volume:22 Page:e859-e869
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Leal Jose Luis^ORCID,Alexander Marliese,Itchins Malinda,Wright Gavin M.,Kao Steven,Hughes Brett G.M.,Pavlakis Nick^ORCID,Clarke Stephen,Gill Anthony J,Ainsworth Hannah,Solomon Benjamin,John Thomas

Funder

Bayer

Merck Sharp and Dohme

Novartis

Eisai

Roche

Sanofi

AstraZeneca

Takeda Pharmaceutical Company

Eli Lilly and Company

Pfizer

Amgen

Bristol-Myers Squibb

Boehringer Ingelheim

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference37 articles.

1. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII);Midha;Am J Cancer Res,2015

2. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies;Jordan;Cancer Discov,2017

3. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy;Skoulidis;Nat Rev Cancer,2019

4. Screening for epidermal growth factor receptor mutations in lung cancer;Rosell;N Engl J Med,2009

5. Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC;Riess;J Thorac Oncol,2018

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion;Current Oncology;2023-11-14

2. Molecular modeling, dynamic simulation, and metabolic reactivity studies of quinazoline derivatives to investigate their anti-angiogenic potential by targeting wild EGFR ^wt and mutant EGFR ^T790M receptor tyrosine kinases;Journal of Biomolecular Structure and Dynamics;2023-11-03

3. A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments;Cancer Treatment Reviews;2023-11

4. Advances in the Diagnosis and Treatment of Advanced Non–Small-Cell Lung Cancer With EGFR Exon 20 Insertion Mutation;Clinical Lung Cancer;2023-11

5. Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non‐small cell lung cancer;Thoracic Cancer;2023-10-05